BMC Pulmonary Medicine最新文献

{"title":"Association between the Body Roundness Index and spirometric parameters among U.S. Adolescents from NHANES 2007-2012.","authors":"Weibang Xu, Baoyi Huang, Yiyi Xu, Ganghua Huang","doi":"10.1186/s12890-025-03739-1","DOIUrl":"https://doi.org/10.1186/s12890-025-03739-1","url":null,"abstract":"<p><strong>Background: </strong>Obesity is an important factor affecting pulmonary function. The Body Roundness Index (BRI) is a new method of assessing body and visceral adiposity, but its association with spirometric parameters in adolescents has not been previously reported.</p><p><strong>Methods: </strong>Cross-sectional data were obtained from the 2007 to 2012 National Health and Nutrition Examination Survey (NHANES), with participants having complete data on BRI and spirometric parameters. A generalized linear regression was conducted to explore the independent relationship between BRI and spirometric parameters. Smoothing curve fitting, subgroup analysis, and interaction tests were also performed.</p><p><strong>Results: </strong>A negative correlation was observed between BRI and pulmonary function. In the fully adjusted model, an increase of one unit in BRI was associated with an increase of 0.08 L in FVC, an increase of 0.04 L in FEV1, an increase of 5.17 L/min in PEF, and a decrease of 0.62% in FEV1/FVC.</p><p><strong>Conclusion: </strong>The results suggest an inverse association between BRI and pulmonary function. However, the clinical significance of this finding warrants further study.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"270"},"PeriodicalIF":2.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term maternal and fetal outcomes of pulmonary hypertension in pregnancy in the southwest plateau area of China: a retrospective study.","authors":"XinDan Zhang, LiLi Tao, XiaoMing Yin, Wei Huang, Pu Li","doi":"10.1186/s12890-025-03729-3","DOIUrl":"https://doi.org/10.1186/s12890-025-03729-3","url":null,"abstract":"<p><strong>Objective: </strong>The objective was to investigate maternal, obstetric, and neonatal outcomes of pulmonary hypertension (PH) in pregnancy based on different altitudes of residence in the southwest plateau area of China.</p><p><strong>Methods: </strong>Data were collected from pregnant women with PH admitted to The First People's Hospital of Yunnan Province from January 1, 2012, to December 31, 2021. All pregnant women with PH were diagnosed via echocardiography according to a pulmonary arterial systolic pressure > 30 mmHg. Patients were classified into three groups according to the altitude of residence during pregnancy. Demographic characteristics, maternal and neonatal outcomes, complications, and follow-up outcomes after discharge were reported.</p><p><strong>Results: </strong>Fifty-two pregnant women with PH were included. Among the included women, eleven (21.2%) were in the low-altitude group, twenty-six (50.0%) were in the medium-altitude group, and fifteen (28.8%) were in the high-altitude group. The overall mortality rate was 5.8%: death up to 6 weeks after delivery occurred in one patient (1.9%), and the other two patients (4.9%) died within one to four years after delivery. Preterm delivery occurred in 22 (42.3%) patients. The incidences of maternal death (11.5% vs. 0.0, p < 0.01), cesarean delivery (80.8% vs. 70.7% vs. 80.0%, p = 0.001), and live birth (84.6% vs. 72.7% vs. 80.0%, p < 0.01) were higher in the medium-altitude group than in the low- and high-altitude groups. Therapeutic abortion was performed in 15.4% of the women, with the highest rate in the high-altitude group (p < 0.01). The rates of heart failure and respiratory failure were highest in the low-altitude group (p < 0.01). No fetal death occurred, and 22 neonates (42.3%) had a low birth weight. During a median follow-up of 2.4 years, two patients died (4.9%), and seven (17.1%) still had PH.</p><p><strong>Conclusion: </strong>The in-hospital mortality rate of pregnant women with PH in the plateau area is similar to that previously reported in the low-altitude region, but the long-term survival rate is lower. Therapeutic abortion is also higher in pregnant women with a high altitude of residence. These findings highlight that the risks associated with PH in pregnancy persist beyond delivery and underscore the importance of early risk assessment, rigorous multidisciplinary management, and prolonged postpartum follow-up, especially in plateau populations with limited access to specialized care.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"272"},"PeriodicalIF":2.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonia: a retrospective observational study.","authors":"Xin Sun, Wenyan Zhu, Chunsheng Zhou, Peijun Xue, Zongru Li, Weihong Zhang, Jiuliang Zhao, Ting Zhang, Min Peng, Juhong Shi, Chen Wang","doi":"10.1186/s12890-025-03736-4","DOIUrl":"https://doi.org/10.1186/s12890-025-03736-4","url":null,"abstract":"<p><strong>Background: </strong>Patients with anti-neutrophil cytoplasmic antibody (ANCA)-positive interstitial lung disease (ILD) but without evidence of systemic vasculitis have been reported in studies and are classified as isolated ANCA-positive idiopathic interstitial pneumonia (IIP). However, the clinical significance of ANCA, particularly myeloperoxidase (MPO) -ANCA in IIP remains poorly understood. This study aims to investigate the differences between ANCA-positive and ANCA-negative IIP patients and further explore the impact of MPO-ANCA on clinical manifestations and prognostic outcomes.</p><p><strong>Methods: </strong>We reviewed 408 ILD patients with available ANCA results from January 2012 to September 2021. 61 patients diagnosed with microscopic polyangiitis-associated ILD were not included in the analysis. A comparative analysis was performed between 61 isolated ANCA-positive IIP patients (ANCA-IIP group) and 286 ANCA-negative IIP patients (IIP group). We further conducted subgroup analyses based on the status of MPO-ANCA.</p><p><strong>Results: </strong>Baseline clinical characteristics, pulmonary function tests, radiological features and all-cause mortality were similar between ANCA-IIP and IIP groups. When comparing the MPO-ANCA-IIP group with the IIP group and the non-MPO-ANCA-IIP group separately, a higher proportion of fibrotic features was observed on imaging (P = 0.004 vs IIP group; P = 0.031 vs non-MPO-ANCA-IIP group). After one year of treatment, the MPO-ANCA-IIP group showed a significantly greater decline in pulmonary function parameters compared to both the IIP group and the non-MPO-ANCA-IIP group. The frequency of pulmonary function decline was significantly higher in the MPO-ANCA-IIP group compared to the non-MPO-ANCA-IIP group (P = 0.026). Additionally, MPO-ANCA was not found to be statistically associated with mortality among patients with IIP.</p><p><strong>Conclusion: </strong>ANCA-IIP patients had similar clinical characteristics and prognoses with IIP patients. MPO-ANCA-IIP patients had more prominent fibrosis on imaging and a greater decline in pulmonary function following treatment. Special attention should be paid to MPO-ANCA positivity during the diagnosis and treatment of IIP patients.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT04413149, May 2020.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"271"},"PeriodicalIF":2.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil percentage-to-albumin ratio (NPAR) as a biomarker for asthma: a cross-sectional analysis of NHANES data.","authors":"Lingge Bi, Jinguang Liang, Kai Hu","doi":"10.1186/s12890-025-03701-1","DOIUrl":"https://doi.org/10.1186/s12890-025-03701-1","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to access the neutrophil percentage-to-albumin ratio (NPAR) as a potential biomarker for asthma risk and to explore its association with asthma incidence in a nationally representative adult population.</p><p><strong>Methods: </strong>We analyzed cross-sectional data from 17,800 adults in the National Health and Nutrition Examination Survey (NHANES 2009-2018). NPAR was calculated as the ratio of neutrophil percentage to serum albumin concentration. Multivariable logistic regression models adjusted for demographic, socioeconomic, clinical, and laboratory covariates were employed to assess NPAR-asthma associations. Missing data were addressed via multiple imputations, and model performance was evaluated using receiver operating characteristic (ROC) curves with bootstrap validation. Restricted cubic splines analyzed non-linear relationships, while subgroup analyses tested effect heterogeneity across demographic and clinical strata. Sensitivity analyses compared complete-case and imputed datasets.</p><p><strong>Results: </strong>Elevated NPAR levels were strongly associated with increased asthma risk. In fully adjusted models, each one-unit increase in NPAR corresponded to a 2.6% rise in asthma prevalence (adjusted OR = 1.026, 95% CI: 1.008-1.045, P = 0.0046). ROC curve analysis demonstrated an AUC of 0.699 for NPAR in predicting asthma. Subgroup analyses revealed effect modification by sex, race, and cardiovascular disease history, though interaction terms did not meet Bonferroni-adjusted significance thresholds. Restricted cubic spline analyses indicated a U-shaped dose-response relationship, with minimal risk observed at NPAR values of 12-15, suggesting dual pathological mechanisms: oxidative stress susceptibility at lower NPAR values and neutrophilic inflammation dominance at higher values.</p><p><strong>Conclusion: </strong>This study provides the first epidemiological evidence supporting NPAR as an independent biomarker for asthma risk. The U-shaped association highlights the complex interplay between systemic inflammation and oxidative stress in asthma pathogenesis. While NPAR offers a cost-effective and accessible tool for risk stratification, its moderate predictive performance underscores the need for complementary biomarkers to enhance clinical utility. Future research should integrate serial NPAR measurements and multi-omics profiling to validate its role in asthma management.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"269"},"PeriodicalIF":2.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144179726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of triglyceride glucose and obesity indices with chronic obstructive pulmonary disease in US adults: data from 2013 to 2018 NHANES.","authors":"Jinzhan Chen, Ayun Chen, Shuwen Yang, Fuhan Zhang, Hongni Jiang, Jiaxin Liu, Congyi Xie","doi":"10.1186/s12890-025-03738-2","DOIUrl":"https://doi.org/10.1186/s12890-025-03738-2","url":null,"abstract":"<p><strong>Background: </strong>The impact of insulin resistance (IR) on chronic obstructive pulmonary disease (COPD) has caught increasing attention, and the triglyceride-glucose (TyG) index and related indices are deemed reliable indicators for evaluating IR. Nevertheless, the potential associations of TyG and obesity-related indexes with COPD are currently understudied. Hence, this paper was to inspect the links of TyG and obesity-related indices with COPD.</p><p><strong>Methods: </strong>This was a cross-sectional study based on data from the NHANES 2013-2018. Weighted logistic regression (WLR), restricted cubic sample (RCS), and receiver operating characteristic (ROC) curves were leveraged to examine the links of the TyG index and obesity indices with COPD. The stability of the correlations was also assessed via subgroup analyses.</p><p><strong>Results: </strong>Data from 6383 participants were finally included, including 583 patients with COPD. WLR discovered positive associations of TyG, TyG-body mass index (TyG-BMI), TyG-waist circumference (TyG-WC), and TyG-waist height ratio (TyG-WHtR) with COPD regardless of covariate adjustment (p-value < 0.05, p for trend test < 0.05). After adjusting for all confounders, RCS analysis signaled notable linear links of TyG and obesity-related indices with COPD (p-value < 0.05, p for nonlinear > 0.05). TyG-WHtR showed the highest association with COPD among the indices tested, albeit with limited discriminative ability (AUC = 0.643, 95% CI: 0.619 ~ 0.665). Subgroup analyses further validated the stability and reliability of the results.</p><p><strong>Conclusion: </strong>TyG and its combination with obesity-related indicators are associated with COPD. Among these, TyG-WHtR showed the strongest association with COPD, although causal relationships cannot be inferred and its discriminative ability remained modest. Further prospective studies are warranted to validate these findings.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"268"},"PeriodicalIF":2.6,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of lung transplantation for end stage lung disease with connective tissue disease: a systematic review and meta-analysis.","authors":"Jihong Liu, Rui Zhou, Zhan Li, Yabin Li, Huizhen Li, Miao Liu, Fei Xie","doi":"10.1186/s12890-025-03640-x","DOIUrl":"https://doi.org/10.1186/s12890-025-03640-x","url":null,"abstract":"<p><strong>Background: </strong>Lung transplantation is the most important treatment for end-stage lung disease. However, the clinical outcomes of lung transplantation in patients with connective tissue disease(CTD) complicated with end-stage pulmonary complications are unclear. Consequently, we performed a systematic review and meta-analysis to compare the survival rates and incidences of adverse events between patients with and without CTD who underwent lung transplantation for end-stage lung disease.</p><p><strong>Methods: </strong>We searched the PubMed, Embase, Web of Science, Cochrane, Wanfang, VIP, CNKI, and CBM databases from their inception until October 18, 2023, for eligible studies. A meta-analysis of each study was performed using State14.0 with a 95% confidence interval (CI). A randomized or fixed-effect model was applied according to the heterogeneity test. The systematic review was registered in PROSPERO (CRD42023483687).</p><p><strong>Results: </strong>Our final analysis included 12 publications on 369 patients with CTD and 2,165 without, all of whom underwent lung transplantation. The survival at 1 month (OR = 2.20, 95% CI: 0.75-6.47, P = 0.485), 6 months (OR = 0.61, 95% CI: 0.33-1.14, P = 0.099), 1 year (OR = 1.05, 95% CI: 0.66-1.66, P = 0.982), 2 years (OR = 0.50, 95% CI: 0.23-1.06, P = 0.096), 3 years(OR = 1.11, 95% CI: 0.70-1.78, P = 0.703) and 5 years (OR = 2.08, 95% CI: 1.11-3.91, P = 0.027), grade 3 primary graft dysfunction (PGD) incidence (OR = 1.33, 95% CI: 0.68-2.60, P = 0.184), rejection events incidence (OR = 1.19, 95% CI: 0.61-2.32, P = 0.607) and intensive care unit (ICU) LOS (SMD = 0.54, 95% CI:-0.26-1.34, P = 0.187) were similar between the two groups. Patients with CTD had a greater risk of PGD incidence (OR = 2.91, 95% CI: 1.43-5.95, P = 0.003), a longer post-transplant hospital length of stay (LOS) (SMD = 0.52, 95% CI: 0.09-0.96, P = 0.009) and post-transplant time to extubation (SMD = 0.68, 95% CI: 0.12-1.25, P = 0.023).</p><p><strong>Conclusions: </strong>The survival rate and the incidence of grade 3 PGD in CTD patients after lung transplantation are comparable to those of other patients undergoing lung transplantation for end-stage lung disease. Thus, Lung transplantation should be a strongly considered therapeutic option for patients with CTD who are suffering from end-stage lung disease. Nevertheless, when selecting patients with CTD for lung transplantation, it is crucial to focus on enhancing perioperative management to reduce the burden of hospitalization post-transplantation.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"264"},"PeriodicalIF":2.6,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inspiratory muscle training and aerobic exercise for respiratory muscle strength in myasthenia gravis post-hospitalization- a randomized controlled trial.","authors":"Chia-Ling Chang, Tien-Pei Fang, Hsin-Mao Tsai, Hui-Chin Chen, Shih-Feng Liu, Hui-Ling Lin, Jui-Fang Liu","doi":"10.1186/s12890-025-03733-7","DOIUrl":"https://doi.org/10.1186/s12890-025-03733-7","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have demonstrated the positive effects of long-term inspiratory muscle training (IMT) on inspiratory muscle strength and pulmonary function. However, the benefits of IMT with aerobic exercise (IMT + AE) in patients with myasthenia gravis (MG) remain unclear. This randomized controlled trial aimed to assess the impact of the early, 6-week, moderate-intensity interval IMT + AE on pulmonary function, functional capacity, and respiratory muscle strength in patients with MG post-hospitalization.</p><p><strong>Methods: </strong>Patients with Discharged MG were randomly assigned to either a control group receiving standard medical management or an intervention group undergoing six-week IMT + AE program. Respiratory status was evaluated using the maximum inspiratory/expiratory pressure (MIP/MEP) and pulmonary function tests. Modified Borg dyspnea scores and a six-minute walk test for functional capacity were also employed.</p><p><strong>Results: </strong>Fifty-four participants were assigned to either the control (sixn = 28) or IMT + AE groups (n = 26). At 6 weeks, the IMT + AE group showed significant improvements across all parameters, while the control group only showed notable differences in the modified Borg scale scores and walking distance. MIP improvements were 33.8 ± 36.1 cmH₂O in IMT and 22.1 ± 25.8 cmH₂O in control groups (P = 0.18). The IMT + AE group improvements were more substantial in MEP, modified Borg scale, and 6-minute walk distance, in addition to forced vital capacity (FVC) and FVC % of prediction (0.21 ± 0.24 L and 6.17 ± 6.01%, respectively), while the control group showed decreased volumes (-0.06 ± 0.30 L and - 1.79 ± 9.69%, respectively). FVC improvement was significant with IMT + AE (0.21 ± 0.24 L) vs. reduction in the control group (-0.06 ± 0.3 L; P = 0.001).</p><p><strong>Conclusions: </strong>Implementing six-week moderate-intensity interval IMT + AE effectively enhanced respiratory muscle strength, alleviated dyspnea, improved physical capacity, and increased FVC in patients with MG following hospitalization after discharge.</p><p><strong>Clinical trial registration: </strong>The study was registered in The Clinical Trials Clinical Trial (NCT06624345|| https://www.</p><p><strong>Clinicaltrials: </strong>gov/ ) on October 12, 2024 (retrospectively registered).</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"266"},"PeriodicalIF":2.6,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany.","authors":"Alastair Greystoke, Melinda J Daumont, Caroline Rault, Hannah Baltus, Philip Q Ding, Gabrielle Emanuel, Stefano Lucherini, Lien Vo, Valeria M Saglimbene, Eleanor Ralphs, Cátia Leal, Minouk J Schoemaker, Alexander Katalinic, Annika Waldmann, Winson Y Cheung","doi":"10.1186/s12890-025-03715-9","DOIUrl":"https://doi.org/10.1186/s12890-025-03715-9","url":null,"abstract":"<p><strong>Background: </strong>Recent therapeutic advancements for non-metastatic non-small cell lung cancer (NSCLC) have increased the need for real-world baselines against which future changes in patient management and clinical outcomes can be compared.</p><p><strong>Methods: </strong>Data on patient characteristics, initial treatment, and overall survival (OS) were derived from adult patients diagnosed with stage I-IIIC NSCLC (2010-2020) in a regional Canadian database (Oncology Outcomes [O2]), an English national registry (Cancer Analysis System [CAS]), and four regional German registries (VONKOdb) and retrospectively analyzed separately using analogous methodology.</p><p><strong>Results: </strong>Data from 85,433 patients were analyzed. Stage at diagnosis varied, with proportions with stage I NSCLC ranging from 30.9% (VONKOdb) to 44.2% (O2) and with stage III disease from 36.9% (O2) to 48.5% (VONKOdb). Across the data sources, proportions receiving surgery ± other treatments were similar for stages I and II, but decreased through stages IIIA, IIIB, and IIIC (range, 24.7-42.7%, 4.6-21.8%, and 0.9-7.5%, respectively). Overall, 70.3-85.2% of patients received active treatment for NSCLC, with a trend toward lower proportions among those with stage III disease. Reached median OS tended to be longest in patients with resected stage I/II NSCLC (range, 28.8-128.0 months) and shortest in patients with stage IIIB/IIIC disease treated with systemic anticancer therapy (SACT) alone, radiotherapy alone, or SACT + palliative radiotherapy (range, 4.8-21.2 months).</p><p><strong>Conclusions: </strong>These data provide insights into treatment pathways and survival outcomes before the widespread use of immunotherapy-based and targeted therapies and will serve as an important baseline for future evaluations of emerging treatments for patients with non-metastatic NSCLC.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"265"},"PeriodicalIF":2.6,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of bronchial stenosis in ulcerative colitis.","authors":"Umberto Zanini, Almerico Marruchella, Giuseppe Paciocco, Francesca Bono, Giulia Bonaiti, Francesco Ammatuna, Paola Faverio, Fabrizio Luppi","doi":"10.1186/s12890-025-03639-4","DOIUrl":"https://doi.org/10.1186/s12890-025-03639-4","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC), are chronic inflammatory disorders of the gastrointestinal tract with increasing incidence worldwide. Though primarily affecting the digestive system, IBD can lead to extraintestinal manifestations, including rare respiratory complications.</p><p><strong>Case presentation: </strong>In our case report, we present the case of a 56-year-old woman with a history of UC and bronchiectasis who developed bronchial stenosis, manifesting as worsening cough and bronchospasm. Initial treatment with corticosteroids and biologic therapy was unsuccessful. The patient subsequently underwent bronchoscopic dilatation interventions, improving her bronchial stenosis and respiratory symptoms. Maintenance therapy with corticosteroids was initiated, while gentamicin was locally administered during the procedures to control infection due to high-load colonization by Pseudomonas.</p><p><strong>Conclusion: </strong>This case underscores the importance of early diagnosis and a multidisciplinary treatment approach to managing complex IBD-related respiratory involvement. Future research on targeted therapies and personalized management strategies is needed to improve outcomes for patients with these rare complications.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"267"},"PeriodicalIF":2.6,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the role of serum adiponectin and its holigomerization in fibrotic interstitial lung diseases: results from a cross-sectional study.","authors":"Ersilia Nigro, Vito D'Agnano, Raffaella Pagliaro, Marta Mallardo, Andrea Bianco, Carmine Picone, Adolfo Gallipoli D'Errico, Aurora Daniele, Fabio Perrotta","doi":"10.1186/s12890-025-03706-w","DOIUrl":"https://doi.org/10.1186/s12890-025-03706-w","url":null,"abstract":"<p><p>Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients might lead to a progressive reduction of respiratory capacities and chronic respiratory failure. Nowadays, biomarkers for predicting the ILD progression and response to therapies are lacking. Adiponectin, the most abundant peptide secreted by adipocytes, has emerged as a potential response biomarker in fibrotic progressive ILDs. The aim of this observational prospective single-center cross-sectional study is therefore to verify whether serum adiponectin levels were altered in patients with fibrotic ILDs (f-ILDs) and its correlation with clinical and pulmonary function data. Sixty-four f-ILDs patients - divided in three subgroups IPF, CTD-ILDs and other f-ILDs - and 45 healthy subjects were recruited. Serum adiponectin concentration were measured by enzyme-linked immunosorbent assay (ELISA). Pulmonary function tests and clinical data were systematically collected. The results showed that patients with f-ILDs have reduced circulating levels of serum adiponectin (12.5 [10.8-15.4] versus 19.3 [17.3-20.8] p < 0.001). No significant difference in adiponectin levels were observed in the different f-ILDs subgroups (p = 0.619). Adiponectin levels were not associated with progression of f-ILDs (p = 0.745). High molecular weight adiponectin isoform was highly reduced in patients with f-ILDs. In patients with CTD-ILDs - but not in other subgroups - adiponectin levels were associated with pulmonary function and GAP index. These resuls support a potential role of adiponectin as diagnostic and prognostic biomarker of f-ILDs.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"263"},"PeriodicalIF":2.6,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}